Follow us on Twitter
twitter icon@FreshPatents


Autoimmune Disease patents

      

This page is updated frequently with new Autoimmune Disease-related patent applications.




Markers of alzheimers disease
The use of markers that participate in inflammatory processes and are associated cytokines in the diagnosis, treatment or prophylaxis of diseases is disclosed. Specifically, cytokines are used to diagnose or treat non-neoplastic or non-leukaemic diseases such as autoimmune diseases or neurodegenerative disorders by the process of taking a dna bearing sample from a subject animal and analysing the sample to determine the allelic variants present at one or more of the snp loci at positions −1082, −819 and −592 of the gene encoding il-10.
Immunoclin Ltd.


Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
The present invention relates to methods of generating and expanding hitman embryonic stem cell derived mesenchymal-like stem/stromal cells. These hes-mscs are characterized at least in part by the low level of expression of il-6.
Imstem Biotechnology, Inc.


Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for fcgammaractivating and fcgammarinhibiting
The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant fc region, wherein said variant fc region comprises at least one amino acid modification relative to a wild-type fc region, which variant fc region binds an fcγr that activates a cellular effector (“fcγractivating,” such as fcγriia or fcγriiia) and an fcγr that inhibits a cellular effector (“fcγrinhibiting,” such as fcγriia) with an altered ratio of affinities relative to the respective binding affinities of such fcγr for the fc region of the wild-type immunoglobulin. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by fcγr is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by fcγr is desired (e.g., inflammation, autoimmune disease)..
Macrogenics, Inc.


Heterocyclic compounds as pi3k-y inhibitors
Or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of pi3k-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .

Heterocyclic compounds and use thereof
Heterocyclic compounds of formula (i) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation.
National Health Research Institutes


Quinazoline and quinoline compounds and uses thereof
This invention provides compounds of formula (i) or a pharmaceutically acceptable salt thereof, wherein t, j, r, r4, rq, o, ra, w and rb and subsets thereof are as described in the specification. The compounds are inhibitors of nampt and are thus useful for treating cancer, inflammatory conditions, and/or t-cell mediated autoimmune disease..
Millennium Pharmaceuticals, Inc.


Inhibitors of trka kinase
The present invention is directed to the compounds of formula i which are inhibitors of tropomyosin-related kinase a (trka): formula (i) or steroisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof, wherein, ra, rb, rc, rd, r1, r2, l and het-ar are as defined herein. These compounds can be used for the preventive and/or therapeutic treatment of diseases or disorders associated with abnormal activities of nerve growth factor (ngf) receptor trka such as pain, inflammation or an inflammatory diseases, cancer, atherosclerosis, restenosis, thrombosis, neurodegenerative diseases, erectile dysfunction (ed), skin disorders, autoimmune disease like multiple sclerosis, sjögren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination..
Gvk Biosciences Private Limited


Covalent inhibitors of cdk-7
Wherein r0, r1, r2, r3, r4, r5, and l are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds..

Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

Method of assessing rheumatoid arthritis by measuring anti-ccp and anti-pik3cd
The present invention relates to a method aiding in the assessment of rheumatoid arthritis (“ra”). The method is used in assessing ra in vitro.
Roche Diagnostics Operations, Inc.


Cyclic dinucleotides useful for the treatment of inter alia cancer

Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.

Novel compound useful for the treatment of degenerative and inflammatory diseases

A novel compound able to inhibit jak is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6.. .
Galapagos Nv

[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

Or a salt thereof, wherein r1, r2, r3, r4, r5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds.

Interferon alpha antibodies and their uses

The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (ifn) alpha subtypes but do not substantially inhibit the biological activity of ifn alpha 21 or the biological activity of either ifn beta or ifn omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided.
E. R. Squibb & Sons, L.l.c.

Cyclodextrin-based polymers for therapeutic delivery

Provided are methods relating to the use of cdp-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are cdp-therapeutic agent conjugates, particles comprising cdp-therapeutic agent conjugates, and compositions comprising cdp-therapeutic agent conjugates..
Cerulean Pharma Inc.

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .
4d Pharma Research Limited

Pan-elr+ cxc chemokine antibodies

Antibodies are provided that specifically bind seven human elr+ cxc chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (ibd), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer..
Eli Lilly And Company

Use of binding molecule specifically binding to precursor of brain-derived neurotrophic factor

Disclosed herein is use of a binding molecule which specifically binds to a precursor of brain-derived neurotrophic factor (probdnf). The binding molecule for probdnf, especially a monoclonal antibody against probdnf, can be used to prevent, mitigate or treat autoimmune diseases..
Shanghai Yile Biotechnology Co., Ltd.

Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Novel synthetic biology-based adcc technologies are provided that enhance or enable adcc responses, for example, through a rationally-designed soluble universal adcc enhancer protein (suaep) where a high-affinity cd3-binding domain is fused to a high-affinity fc-binding domain. The suaep technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable..
1globe Biomedical Co., Ltd.

Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases

A-x−4x−3x−2x−1-b (seq id no: 3)   (i). .

4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors

Compounds of formula i: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which r1, r2, r3 and r4 have the meanings given in the specification, are inhibitors of one or more jak kinases and are useful in the treatment of jak kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.. .
Celgene Corporation

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.. .

Carbazole derivatives

Disclosed are compounds of formula (i): (i) or a salt thereof, wherein q, r1a, r1b, r2a, r2b, r3, r4, r5a, r5b, r6a, r6c, r7a, r7b, r7c, and r7d are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company

Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease

Described herein are methods and compositions relating to the treatment of e.g., cancer, autoimmune disease, immune deficiency, and/or neurodegenerative disease. In some embodiments, the methods of treatment relate to administering a compound as described herein.
The Jackson Laboratory

Compositions and methods for the depletion of cd117+ cells

The invention provides compositions and methods useful for the depletion of cd117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of cd117+ cells in a patient, such as a human.
Magenta Therapeutics, Inc.

Compositions and methods for t cell delivery of therapeutic molecules

The present invention includes compositions and methods for modifying a t cell with a nucleic acid encoding a switch molecule comprising an extracellular domain comprising a membrane receptor or fragment thereof and an intracellular domain comprising a signaling receptor or fragment thereof. In one aspect, a method comprises introducing a nucleic acid encoding a switch molecule and a nucleic acid encoding a soluble fusion protein and/or a nucleic acid encoding a bispecific antibody into a population of cells comprising t cells, wherein the t cells transiently expresses the switch molecule and soluble fusion protein or bispecific antibody.
The Trustees Of The University Of Pennsylania

Compositions containing a spiranthes sinensis extract and pharmaceutical applications thereof

The present disclosure provides compositions and dosage forms comprising sinetirucallol, and methods of using such compositions, such as to treat an inflammation-associated disease, liver fibrosis, wound healing, and/or an autoimmune disease. In some embodiments, the composition comprises a spiranthes sinensis extract..
Spiranthes Biotech, Llc

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .
4d Pharma Research Limited

Methods and compositions for treating autoimmune disorders by targeting kv1.3 ion channels with functionalized lipid-derived nanovesicles

Synthesis and pharmaceutical compositions of antibody-functionalized nanovesicles encapsulating ion channel knockout sirna, and methods of treating autoimmune diseases associated with increased expression and/or hyperactivity of t cells by selectively targeting memory t cells with the nanoparticles, which deliver their sirna cargo into the cytosol of the tm cell thus reducing ion channel expression and decreasing ca2+ influx.. .
North Carolina Agricultural And Technical State University

Peptides for modulating t-cell activity and uses therof

The present invention provides methods and materials for treating and preventing autoimmune diseases. In particular, the present invention relates to the discovery that small peptides are capable of interacting with cd40, thereby interfering with the ability of cd40 to interact with cd154, which is important in inflammation.
The Regents Of The University Of Colorado, A Body Corporate

Bicyclic heteroaryl amine compounds

Disclosed are compounds of formula (i) or a salt thereof; wherein: x is n or ch; q1 is: (i) cl, br, i, —cn, —ch3, or —cf3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 ra and zero to 1 rb; and r1, r2, r3, r4, r5, r6, ra, and rb are defined herein. Also disclosed are methods of using such compounds as modulators of pi3k, and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company

Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors

Disclosed are compounds of formula (i); or a salt thereof; wherein qi is (i) cl, br, i, —cn, —ch3, or —cf3; or (ii) pyrazole, triazole, or pyridinyl, each substituted with r1; q2 is pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with r2 and r3; and r1, r2, and r3 are defined herein. Also disclosed are methods of using such compounds as modulators of pi3k, and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company

Tricyclic atropisomer compounds

Disclosed are compounds of formula (i): or a salt thereof, wherein q is: or; and x, r1a, r1b, r3, r4, and r5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .
4d Pharma Research Limited

Monitoring health and disease status using clonotype profiles

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Adaptive Biotechnologies Corp.

Anti-cd52 antibodies

Anti-human cd52 antibodies and antigen-binding fragments thereof are provided. Also provided are isolated nucleic acids, recombinant vectors and host cells for making the antibodies and fragments.
Genzyme Corporation

Antagonistic anti-ox40l antibodies and methods of their use

Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-ox40l antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory t cells but also promote the generation and function of regulatory t cells by inducing il-10 and inhibiting tnf-α and by reducing aberrant th2 cell responses.
Baylor Research Institute

Heterocyclic derivatives as rorgamma modulators

The present invention provides novel compounds of formula (i) that are modulators of rorgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of rorgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, fibrotic diseases, or cholestatic diseases..
Genfit

Competitive inhibitors of invariant chain expression and/or ectopic clip binding

The invention relates to methods for modulating the immune function through targeting of clip molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, alzheimer's disease, allergic disease, transplant and cell graft rejection, hiv infection and other viral, bacterial, and parasitic infection, and aids.
Regents Of The University Of Colorado, A Body Corporate

Compositions containing omega-3 oil and uses thereof

The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules.
Maine Natural Health Company, Inc.

Composition for alleviating nephrotoxicity caused by immunosuppressive drug, comprising metformin, and composition for preventing or treating immune disease, comprising the same

Provided is a composition for alleviating nephrotoxicity caused by an immunosuppressive drug, including metformin, and a composition for preventing or treating an immune disease, including the same. Further, the composition provided can be useful in improving a treatment effect on diseases requiring immunosuppression by effectively alleviating a decline in renal function caused due to side effects of conventional immunosuppressive drugs, and can also be useful in preventing or treating organ transplant rejection, autoimmune diseases, inflammatory diseases and the like since various methods of co-administering a conventional immunosuppressive drug and metformin are suggested to reduce nephrotoxic side effects of conventional immunosuppressive drugs and maximize immunosuppressive or immunomodulatory effects..
The Catholic University Of Korea Industryacademic Cooperation Foundation

Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases

Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.. .
Nuevolution A/s

Tolerogenic dendritic cells, methods of producing the same, and uses thereof

Described herein are methods for the preparation of stable semi-mature tolerogenic dendritic cells and compositions comprising such stable semi-mature tolerogenic dendritic cells. The stable semi-mature tolerogenic dendritic cells described herein and compositions thereof can be used for the establishment of immune tolerance when treating an autoimmune disease, graft rejection and/or graft-versus-host disease..
Sotio A.s.

Altering gene expression in cart cells and uses thereof

The present invention relates to compositions and methods for generating a modified t cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of tcr α chain, tcr β chain, beta-2 microglobulin, a hla molecule, ctla-4, pd1, and fas and further comprising a nucleic acid encoding a modified t cell receptor (tcr) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (car). Also included are methods and pharmaceutical compositions comprising the modified t cell for adoptive therapy and treating a condition, such as an autoimmune disease..
The Trustees Of The University Of Pennsylvania

Vista regulatory t cell mediator protein, vista binding agents and use thereof

The present invention relates to a novel regulatory t cell protein. This protein, designated pd-l3 or vista resembles members of the pd-l1 family, identified a novel and structurally-distinct, ig-superfamily inhibitory ligand, whose extra-cellular domain bears homology to the b7 family ligand pd-l1.
The Trustees Of Dartmouth College

Diaryl macrocycles as modulators of protein kinases

The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.. .
Tp Therapeutics, Inc.

Thienopyranones as kinase and epigenetic inhibitors

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, type 1 or 2 diabetes, obesity, inflammatory disease, or myc-depenent disorder including by modulating biological processes by the inhibition of pi3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of formula i-ix (or pharmaceutically acceptable salts thereof) as defined herein.. .
Signalrx Pharmaceuticals, Inc.

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Compositions and methods for the prevention and treatment of autoimmune conditions

The methods include selectively reducing or expanding t cells according to the antigenic specificity of the t cells. Therefore, the present invention can be used to reduce or eliminate pathogenic t cells that recognize autoantigens, such as beta cell specific t cells.
The General Hospital Corporation

Antioxidant composition containing extracellular polysaccharide produced using ceriporia lacerata as active ingredient

The present invention relates to an antioxidant composition containing an extracellular polysaccharide produced using ceriporia lacerata, or a mycelium culture of ceriporia lacerata comprising the same, or a dry powder or an extract thereof as an active ingredient. The composition can be used as an antioxidant for preventing or treating various diseases such as brain diseases such as stroke, parkinson's disease, etc., heart diseases, ischemia, arteriosclerosis, skin damage, inflammation, rheumatism, autoimmune diseases, etc.
Fugenbio Co., Ltd.

Treatment of ocular inflammatory diseases using laquinimod

Disclosed is a method for treating an ocular inflammatory disease (oid), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an oid, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway.
Teva Pharmaceutical Industries, Ltd.

Novel anti-inflammatory agents

Disclosed are methods of regulating interleukin-6 (il-6) and/or vascular cell adhesion molecule-1 (vcam-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds..
Resverlogix Corp.

Melatonin in autoimmune disease

Methods for treating, or reducing risk of developing, seasonal worsening of multiple sclerosis (ms) in a subject who has ms, comprising administering a melatonin agonist to a subject.. .
The Brigham And Women's Hospital, Inc.

Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient

The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of il-17 and tnf-α, which are inflammatory cytokines, increases the activity of regulatory t cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases.
The Catholic University Of Korea Industry-academic Cooperation Foundation

Diagnosis of an autoimmune disease using detection of antibodies directed against c5a-receptor

The application relates to a method for diagnosis of an autoimmune disease, comprising the step of determining the presence or absence of antibodies directed against csa-receptor in a sample of the subject to be diagnosed, wherein the presence of antibodies directed against csa-receptor is indicative of an autoimmune disease in said subject. Furthermore, the application relates to kits comprising c5a-receptor or an immunogenic fragment thereof and the use of csa-receptor..
Cell Trend Gmbh

Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

This invention provides for a fusion protein between an il2αβγ selective agonist protein (il2 selective agonist) and a igg fe protein. The il2 selective agonist moiety provides a therapeutic activity by selectively activating the il2αβγ form of the receptor, thus selectively stimulating tregs.
Delinia, Inc.

Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases

Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.. .
Nuevolution A/s

Inhibitors of cyclin-dependent kinase 7 (cdk7)

The present invention provides novel compounds of formula (i) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.

Methods of treating autoimmune diseases

Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent tgf-β and/or another agent that promotes expansion of regulatory t cells.
Genzyme Corporation

Novel anti-inflammatory agents

Disclosed are methods of regulating interleukin-6 (il-6) and/or vascular cell adhesion molecule-1 (vcam-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds..
Resveriogix Corp.

Treatment of allergies and autoimmune diseases

The present disclosure provides a method of treating allergies and autoimmune diseases using microsystem acupuncture. Methods provided herein for treating allergies and autoimmune diseases using microsystem acupuncture involving a novel allergy zone.

Therapeutic agent for autoimmune diseases comprising pd-1 agonist

Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients.
Ono Pharmaceutical Co., Ltd.

Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof

Novel activating receptors of the ig super-family expressed on human myeloid cells, called trem(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of trems, trem-1 and trem-2 are disclosed.
Novo Nordisk A/s

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .
4d Pharma Research Limited

Immunosuppressive blood cells and methods of producing the same

The present invention refers to a method of producing immunosuppressive bleed cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease.. .
Universitatsklinikum Heidelberg

Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases

The present disclosure provides compositions and methods of use comprising a matrix metalloproteinase-9 (mmp9) binding protein, alone or in combination with one or more additional therapeutic agents for the treatment or prevention of diseases and conditions.. .
Gilead Sciences, Inc.

Methods of treating autoimmune disease using a domain antibody directed against cd40l

Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (itp), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Bristol-myers Squibb Company

Anti-cd100 antibodies and methods for using the same

Compositions and methods are provided for treating diseases associated with cd100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-cd100 monoclonal antibodies have been developed to neutralize cd100..
Vaccinex, Inc.

Il22 immunoconjugates

The application relates to a conjugate comprising interleukin-22 (il22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ed-a isoform of fibronectin.
Philogen S.p.a.

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Artificial antigen-presenting cells and methods for producing and using the same

Described herein are biomimetic janus particles useful as artificial antigen presenting cells capable of activating t cells in vitro. “bull's eye” ligand patterns mimicking either the native or reverse organization of the t cell immunological synapse are provided on the surface of nano- or micro-sized particles.
Indiana University Research And Technology Corporation

Combination of anti-cd20 antibody and pi3 kinase selective inhibitor

Highly effective combinations of a compound of formula a (a pi3kδ selective inhibitor) and anti-cd20 antibodies are provided herein for the treatment and amelioration of pi3kδ and/or cd20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases.
Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Novel epitope as a target for therapy of inflammatory autoimmune diseases and graft rejection

The present invention relates to a peptide comprising an epitope within the macrophage scavenger receptor b-i, a method of using the same, a nucleic acid encoding the same and an antibody that binds to the epitope.. .
Rappaport Family Institute For Research In The Medical Sciences

Metallic gold cluster molecules as therapeutic agents for arthritic animals

A therapeutic method for attenuating symptoms of inflammation and autoimmune diseases. This method includes preparing and administering to animals intraperitoneally or orally a metallic gold cluster complex preparation..

Methods for increasing the selective efficacy of gene therapy using car peptide and heparan sulfate mediated macropinocytosis

Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome.
Vascular Biosciences

Substituted bicyclic compounds

And/or a salt thereof, wherein r1 is —oh or —op(o)(oh)2, and x1, x2, x3, r2, r2a, ra, rb, and rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.

Oligonucleotide targeted to the a20-three prime untranslated region

An antisense oligonucleotide comprising a sequence targeted to the 3′ untranslated region (3′ utr) of the tnfaip3 (a20) transcript and its use as a medicament, for example in the treatment of cancer or an autoimmune disease.. .

Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases

The invention provides methods for the ex-vivo expansion of cd4+cd25+ tregs. The invention provides a method for producing ex vivo expanded tregs that may be used to inhibit unwanted human immune responses against self-antigens or allergens.

Treatment of il-17 mediated disease by blocking sefir-sefir interactions

A method of treating an il-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the sefir domain of il-17r to the sefir domain of act1. In particular, it has been determined that the αc helix region of the sefir domain of both il-17r and act1 plays an important role in the association of il-17r and act1.

Modulators of ror-gamma receptors, composition and use thereof

The present invention provides novel methods to treat disease by modulating retinoid-related orphan receptor gamma (ror-gamma) in vitro and in vivo with ursolic acid analogs, and compositions thereof. The methods and compounds disclosed herein are useful for inhibiting the differentiation of a population of t cells, or treating a disease related to th17 cell responses in a subject.

Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor

Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as h4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.. .

Conjugates of cell binding molecules with cytotoxic agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (i), wherein t, l, m, n, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, and r13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.. .

Cell populations having immunoregulatory activity, isolation and uses

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (ifn-γ) by expressing indolamine-2,3-dioxygenase (ido) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.. .

Cell populations having immunoregulatory activity, isolation and uses

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (ifn-γ) by expressing indolamine-2,3-dioxygenase (ido) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.. .

Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof

The disclosure provided herein relates generally to mesenchymal-like stem cells “hes-t-misc” or “t-msc” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hes-t-msc or t-msc, t-msc derived cells and cell lineages “t-msc-dl” are also described.
University Of Connecticut

Altering gene expression in modified t cells and uses thereof

The present invention relates to compositions and methods for generating a modified t cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of tcr α chain, tcr β chain, beta-2 microglobulin and fas further comprising a nucleic acid encoding a modified t cell receptor (tcr) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (car). Also included are methods and pharmaceutical compositions comprising the modified t cell for adoptive therapy and treating a condition, such as an autoimmune disease..
The Trustees Of The University Of Pennsylvania

Rna polymerase i inhibitors and uses thereof

Provided are novel compounds which are capable of inhibiting an activity of rna polymerase i, and uses thereof in treating diseases or disorders modulated by rna polymerase i, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.. .
Tel Hashomer Medical Research Infrastructure And Services, Ltd.

Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-tnf-α antibody or antigen-binding fragment thereof and at least one anti-il-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a dnl® complex.
Ibc Pharmaceuticals, Inc.

Immune system modulation for prophylaxis and treatment of diseases and disorders

The invention is directed to biological response modifiers (brm) which may contain one or more compounds, and to methods for enhancement of an immune system with brms of the invention including augmenting a specific immune response either prophylactically or for treatment, as an adjuvant or vaccine when coupled with a pathogenic antigen, and for boosting an immune system generally. The invention is also directed to the reduction of an unrestrained or improper inflammatory response and/or an immune response such as to treat or prevent autoimmune diseases and disorders, and associated symptoms.
Marpe Holdings, Llc

Substituted tetrahydrocarbazole and carbazole carboxamide compounds

R1 is f, cl, —cn, or —ch3; r2 is cl or —ch3; r3 is —c(ch3)2oh or —ch2ch2oh; ra is h or —ch3; each rb is independently f, cl, —ch3, and/or —och3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases

Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of btk, mtor kinase, and bcl-2 or their signaling pathways, and immunomodulatory drugs.
Zhejiang Dtrm Biopharma Co. Ltd.

Cholix toxin-derived fusion moelcules for oral delivery of biologically active cargo

The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the vibrio cholera cholix gene (ntcholix), a variant of cholix truncated at amino acid a386 (cholix386) and the use of other various cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics.
Applied Molecular Transport, Llc

Novel compositions and therapeutic methods

The present invention is directed to novel products, variants, pharmaceutically acceptable salts and prodrugs thereof, and medical use of such compounds for the treatment and/or management of sepsis, septicemia, septic shock, ocular infection, ocular inflammation, ocular angiogenesis, rheumatoid arthritis (ra), atherosclerosis, inflammatory bowel diseases (ibd), asthma, chronic obstructive pulmonary disease, fever syndromes, cachexia, psoriasis, autoimmune diseases, cardiac diseases, retinoblastoma, cancer and/or any disorder associated with inflammation, immunomodulation and microbial infection.. .
Ayuvis Research Llc

Cyclic urea compounds as tropomyosin-related kinase (trk) inhibitors

Tropomyosin-related kinase inhibitors (trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions.
Genzyme Corporation

Bioassay for the early detection of autoimmune diseases

Provided are methods for aiding in diagnosing autoimmune diseases in a mammal, comprising contacting a biological sample that is not a tear sample from the mammal with an antibody that specifically binds to a first polypeptide selected from the group ctss, ctsh, ctsr, ctsw, ctsz, ifng, il-6ra, il-10, il-10ra, il-15, tnfa, apo-f, or lcn-2 or a second polypeptide selected from the group lactoperoxidase, lactoferrin or lysozyme under conditions favoring the formation of an antibody-polypeptide complex, and determining the amount of complex formed, wherein an increased formation of antibody-first-polypeptide complex or a decreased formation of antibody-second-polypeptide complex as compared to a suitable control, indicates a likely positive diagnosis of an autoimmune disease for the mammal, thereby aiding in the diagnosis. Methods of treating the autoimmune diseases are also provided..

Humanized anti-cd22 antibody

Disclosed are humanized rfb4 antibodies or antigen-binding fragments thereof. Therapy of b-cell associated diseases, such as b-cell malignancies, autoimmune disease and immune dysfunction disease.
Immunomedics, Inc.

Benzazepine sulfonamide compounds

Wherein r4 or r5 is —so2—nr7r8 and r1 to r8 and y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof

The invention provides a composition, and method of use thereof, comprising self-antigen displaying nanoparticles to target auto-reactive immune components for treating and/or preventing the autoimmune diseases associated therewith. The nanoparticles can also be loaded with cytotoxic drugs for targeted cell killing or with immune-tolerizing compounds to normalize the immune regulation..
The Regents Of The University Of California

Therapeutic uses of cd137pos regulatory t cells in treating autoimmune diseases

A method for treating or preventing a t-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells. Also provided are pharmaceutical compositions for treating or preventing t-cell-mediated autoimmune diseases, the pharmaceutical compositions including a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells and a pharmaceutically-acceptable carrier..
University Of Cincinnati

Pharmaceutical compositions comprising soluble cd137

A method for treating or preventing a t-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells. Also provided are pharmaceutical compositions for treating or preventing t-cell-mediated autoimmune diseases, the pharmaceutical compositions including a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells and a pharmaceutically-acceptable carrier..
University Of Cincinnati

Methods for treating gi syndrome and graft versus host disease

We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic t lymphocyte (ctls)-induced killing and by damage to endothelial microvasculture, including radiation-induced gi syndrome, graft vs. Host diseases, inflammatory diseases and autoimmune diseases.
Board Of Regents, The University Of Texas System

Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide

Disclosed herein are methods for counteracting age-related decrease in gene expression or treating age-related diseases, for example cancers and autoimmune diseases, caused by decreased expression levels of a gene associated with the apoptosis pathway, using a nitroxide. Further disclosed are methods for treating a human subject in need of an increased expression level of a gene associated with the apoptosis pathway using a nitroxide..

Methods of treating autoimmunity

Methods of treating, ameliorating, or inhibiting the development of autoimmune diseases by modulating the binding of mhc class ii molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease. The binding may be modulated by the administration of d-α-methyldopa, or pharmaceutical compositions comprising therapeutically effective amounts of d-α-methyldopa..
The Regents Of The University Of Colorado, A Body Corporate

Peptide microarrays and novel biomarkers for celiac disease

The present disclosure relates generally to biomarkers and peptide arrays, and, more particularly, to a method of using a peptide array to identify biomarkers for an autoimmune disease such as, e.g., celiac disease. Furthermore, a set of novel biomarkers for celiac disease, having high sensitivity and specificity, are disclosed in addition to method of treatment using the novel biomarkers..
Vibrant Holdings, Llc

Intracellular osteopontin regulates the lineage commitment of lymphoid subsets

Methods for diagnosing and prognosing autoimmune diseases and t cell lymphomas are provided, for example by measuring levels of intracellular osteopontin (opn-i). Also provided are screening methods for identifying activators and inhibitors of the transcription factor bcl6, which is involved in t cell activation/differentiation.
Dana-farber Cancer Institute, Inc.

Fused amino pyridine as hsp90 inhibitors

The present invention relates to hsp90 inhibitors containing fused amino pyridine core that are useful as inhibitors of hsp90 and their use in the treatment of hsp90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.. .
Curis, Inc.

Indole compounds and pharmaceutical use thereof

Wherein each symbol is as described in the specification. The invention also provides a method for the treatment or prophylaxis of inflammatory diseases, allergic diseases, autoimmune diseases, transplant rejection or the like in a mammal by administering the compound or pharmaceutically acceptable salt thereof or solvate thereof to the mammal..

Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
Immunomedics, Inc.

Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease

Disclosed are methods, compositions and uses of concentrated formulations of anti-cd74 antibody, of use for treating autoimmune diseases. In a specific non-limiting embodiment, the autoimmune disease is systemic lupus erythematosus (sle).
Immunomedics, Inc.

Method and kit for the predictive prognosis of responsiveness to treatments of autoimmune diseases

The present invention relates to the use of one or more mhc class i molecules dextramers (dextramers®) associated with peptides corresponding to apoptotic epitopes of human cd8+ t cells for the predictive prognosis of responsiveness or non-responsiveness to treatments and/or for monitoring the therapeutic effectiveness of treatments with biological medicaments that block and/or inhibit tnf, and/or biological medicaments that block and/or inhibit cytokines or cytokine receptors and/or biological medicaments against b cells and/or biological medicaments that inhibit t cell co-stimulation in patients affected by autoimmune diseases, together with methods and kits for said predictive prognosis.. .
Universita' Degli Studi Di Roma "la Sapienza"

Oral administration of an anti-cd20 antibody for treatment of autoimmune disease

The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of an anti-cd20 antibody is administered to the subject.

Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions

Provided are compositions, including isolated, synthetic or recombinant peptides for: expanding regulatory t cells (treg) populations; for treating or ameliorating a vascular inflammation, and kawasaki disease (kd) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities, and acute or chronic vascular inflammatory abnormalities, and methods for making and using them. Provided are immunotherapies for promoting expansion of natural, treg to establish, or re-establish, vascular homeostasis; or, for ameliorating: a disease or condition associated with an autoimmune disease or condition; an immune-mediated vascular disorder; a disease or condition treated with intravenous immunoglobulin (wig) therapy; a vascular coronary abnormality; an acute or a chronic vasculitis; an autoimmune inflammatory vasculitis; a t cell mediated pediatric vasculitis; kawasaki disease (kd) or a pediatric acute vasculitis of the coronary arteries; atherosclerosis; preventing miscarriage in autoimmune women; rheumatoid arthritis or juvenile idiopathic arthritis; a neoplastic hematological disorder, or a leukemia..
The Regents Of The University Of California

Indole carboxamide compounds

Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

Pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis and treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis

The present disclosure provides a pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis, including: an effective amount of an extract of a plant belonging to rutaceae as an effective ingredient for treating or alleviating the autoimmune disease and/or complication thereof and/or nephritis, wherein the autoimmune disease is selected from a group consisting of lupus erythematosus, psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, crohn's disease and ulcerative colitis (uc).. .
Industrial Technology Research Institute

Methods and compositions for modified t cells

The present invention relates to compositions and methods for generating modified cells with nucleic acid encoding a t cell receptor (tcr), a nucleic acid encoding a bispecific antibody, affinity molecule chimeric receptor, bispecific affinity molecule, or a chimeric ligand engineered activation receptor (clear). One aspect includes a method for generating a modified t cell.
The Trustees Of The University Of Pennsylvania

Fgl2 expressing regulatory t cells

This application relates to methods and compositions for inducing immune tolerance. Specifically, methods and uses of regulatory t cells (treg) and associated compositions for the induction of immune tolerance are described.
Veritas Therapeutics Inc.

Therapeutic detoxification compositions and methods of making and using same

A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.. .
Immutrix Therapeutics, Inc.

Treatments for autoimmune disease

The invention relates to a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis. In a further embodiment of the invention there is provided a molecule capable of acting as substrate for the queuine-insertase enzyme complex and where said molecule is not a substrate for hypoxanthine-guanine phosphoribosyltransferase and said molecule has the effect of lowering interferon gamma, for use in the treatment of auto-immune diseases.
The Provost, Fellows, Foundation Scholars, And The Other Members Of Board,of The College Of The Holy

Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor

Described herein are pharmaceutical formulations of bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Method for the detection of antigen presentation

The present invention pertains to a method for detecting antigen presentation via antigen presenting molecules such as major histocompatibility complex (mhc) class i or ii. The invention deploys a first binding agent specific for the antigen epitope and a second binding agent specific for the antigen presenting molecule.
Deutsches Krebsforschungszentrum Stiftung Des öffentlichen Rechts

Novel imidazopyridazine compounds and their use

This disclosure provides novel imidazopyridazine compounds of formula (i) and pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a process for preparing them, and their practical effect in inhibiting pi3k and potential use in treating a disease responsive to inhibition of pi3k, for example, an inflammatory disease, autoimmune disease or cancer.. .
Hutchison Medipharma Limited

Probiotic bifidobacterium adolescentis strains

The present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated with human pbmc derived dendritic cells. The strains may have one, two or all three of these capabilities.
Chr. Hansen A/s

Method for treating parkinson disease, neurodegenerative disorders, and autoimmune diseases

The embodiments herein relate to a therapeutic method for the treatment of parkinson disease, other neurodegerative disorders, and autoimmune diseases. The method includes providing sodium thiosulfate through any method of administration (orally, intravenously, through inhalation, intravesically, vaginally, rectal route, sublingually, ophthalmically, or topically) and is given with one or more pharmaceutically acceptable carriers or excipients.

Nucleic acid capable of inhibiting expression of beta-2gpi

The present invention provides a nucleic acid having activity to suppress expression of β2gpi, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as aps, sle and the like and thrombosis in hemodialysis.. .
Kyowa Hakko Kirin Co., Ltd.

Nucleic acid capable of inhibiting expression of beta-2gpi

The present invention provides a nucleic acid having activity to suppress expression of β2gpi, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as aps, sle and the like and thrombosis in hemodialysis.. .
Kyowa Hakko Kirin Co., Ltd.

Modulation of ptpra to treat arthritis

Presented is a method for treating inflammation and autoimmune diseases through the use of a phosphatase rheumatoid arthritis (pt-pra) antagonist.. .
The Regents Of The University Of California

Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases

The present invention pertains to the field of immunoterapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (mdsc) into non suppressive cells, by administering a compound blocking the interaction between sirpa and cd47 to a patient in need thereof in order to reduce mdsc-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation..
Ose Immunotherapeutics

Methods of treating inflammatory and autoimmune diseases with natalizumab

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, crohn's disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment.
Biogen Ma, Inc.

T-cell redirecting bispecific antibodies for treatment of disease

The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.
Ibc Pharmaceuticals, Inc.

Targeted delivery of tertiary amine-containing drug substances

Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed..
Seattle Genetics, Inc.

(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability

The invention relates to solid pharmaceutical compositions comprising (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.. .
Sanofi

Concentrated methotrexate solutions

Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml..
Medac Gesellschaft Fuer Klinische Spezialpraepararate Mbh

Anti-pd-1 monoclonal antibody and obtaining method therefor

The invention provides human monoclonal antibodies that specifically bind to pd-1 with high affinity. The anti-pd-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed.
Beijing Jingyitaixiang Technology Development Co., Ltd.

Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28

Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human cd28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody.
Bristol-myers Squibb Company

Modulating gamma-c-cytokine activity

Peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases

Y is c, n or s.. .

Compounds that expand hematopoietic stem cells

The present invention relates to compounds and compositions for expanding the number of cd34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (hscs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense..
Novartis Ag

Method for inducing a sustained immune response

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (hiv) acquired immune deficiency syndrome (aids, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
Immune Therapeutics Inc.

Method for inducing a sustained immune response

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (hiv) acquired immune deficiency syndrome (aids, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
Immune Therapeutics Inc.

Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions

Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases.. .
Caliper Life Sciences, Inc.

Methods and kits for screening transplant recipients and candidates

Methods and kits are provided for determining of immunoglobulin isotypes and subclasses in a subject. In general the subject is a human who is a transplant candidate recipient or recipient, has allergies, or has an autoimmune disease.
National Institute Of Transplantation Foundation

Antibodies specific for mmp9

The present invention relates to new proteins that bind to mmp9 and comprise at least one fragment of a heavy chain variable region and/or at least one fragment of a light chain variable region of an antibody. In particular, the mmp9 binding proteins according to the invention are able to neutralize mmp9 activity and are useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases or cancers.
Merck Patent Gmbh

Anti-cd40 antibodies and uses thereof

Antibodies and antibody fragments that bind to human cd40 and inhibit interaction between cd40 and its ligand, cd40l are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit hyperactivation of b or t cells and treat or prevent disorders such as autoimmune diseases..
Biogen Ma Inc.

Antibody therapeutics that bind ctla4

There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Novel compounds

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants..

Flt3 receptor antagonists

The invention pertains to novel flt3 receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases..
UniversitÉ De Strasbourg

Soluble mediator

The present disclosure relates to a soluble cd52 glycoprotein and its use in treating diseases regulated by effector t-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of cd52, and to diagnostic methods based on the detection of cd52 expression levels in a subject..
The Walter And Eliza Hall Institute Of Medical Research

Aza-heteroaryl compounds as pi3k-gamma inhibitors

And pharmaceutically acceptable salts thereof, wherein x, y, z, a, w, r4, r5, and r6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (pi3kγ) and are useful in the treatment of diseases related to the activity of pi3kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .



Autoimmune Disease topics:
  • Autoimmune Disease
  • Immune Disease
  • Autoimmune
  • Autoimmune Diseases
  • Immune Diseases
  • Transplant
  • Infectious Disease
  • Infectious
  • Inflammatory Disease
  • Antagonist
  • Rheumatoid Arthritis
  • Proliferative
  • Nucleotide
  • Antibodies
  • Infectious Diseases


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Autoimmune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3744

    file did exist - 13806

    0 - 1 - 251